Inflammation and Electroconvulsive Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

5 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-08-31

Study Completion Date

2017-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to explore whether electroconvulsive therapy (ECT) accidentally leads to a side effect of brain inflammation. Patients with treatment resistant depression who are planning to take ECT will be subsequently approached to participate in the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inflammatory Markers as Predictors of the Efficacy of Electroconvulsive Therapy (ECT) in Major Depression Patients

NCT06439797

Major Depressive Disorder Healty Controls

COMPLETED

Evaluating the Efficacy of Magnetic Seizure Therapy in Treatment Resistant Depression.

NCT01748708

Depressive Disorder

WITHDRAWN NA

Exploring Effects of Electroconvulsive Therapy on the Human Brain in Depression - The Danish ECT/MRI Study

NCT03040388

Depressive Disorder Depression Depressive Disorder, Major

COMPLETED

Mechanism of Action of Electroconvulsive Therapy

NCT04059952

Unipolar Depression Bipolar Depression

COMPLETED

Can Magnetic Brain Stimulation Help Prevent Relapse in Depression?

NCT02029963

Major Depressive Disorder

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The first scan will take place before the first ECT session. The second scan will occur after a minimum of six ECT sessions (average 2.5 weeks). Secondary measures will include mood symptom severity, neurocognitive measures, peripheral inflammatory markers and TSPO genotype.

The hypothesis is that neuroinflammation will be increased by ECT.

There will be no alterations to standard care of depressed patients due to participation in the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ECT and Treatment Resistant Depression

Subjects will be those with diagnosis of major depressive disorder that have not responded to many different treatments and who are planning to take electroconvulsive therapy (ECT). This group will receive two \[18F\]FEPPA PET scans, one baseline and one after an average of 2.5 weeks of ECT treatments.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* stable physical health
* diagnosis of non-psychotic, non-catatonic, major depressive disorder, either unipolar or bipolar and a non-response to at least three clinical trials at appropriate dose of antidepressant medication from at least three different pharmacological classes
* at least a 17 on the17-item HDRS despite taking antidepressant treatment prior to ECT
* have not received ECT within the last 12 weeks

Exclusion Criteria

* currently pregnant
* current substance abuse or dependence
* neurological or unstable medical illness
* use of anti-inflammatory drugs within the past month
* diazepam or other benzodiazepine use within the past month, except for lorazepam and clonazepam

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No